Education
About Us
Working with TipRanks
Follow Us
Belite Bio, Inc. ADR (BLTE)
NASDAQ:BLTE
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.35Last Year’s EPS
-0.27Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 17, 2025
|% Change Since: -3.62%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Neutral
The earnings call presented both positive and negative aspects. Significant advancements and regulatory designations for Tinlarebant, along with strong clinical trial enrollment and financial stability, were highlighted as major achievements. However, increased expenses, net loss, adverse events in trials, and high dropout rates were notable challenges. Despite the challenges, the overall sentiment was cautiously optimistic due to strong progress in clinical trials and financial stability.Company Guidance
During Belite Bio's fourth quarter and full year 2024 earnings call, significant guidance was provided regarding the progress of their flagship drug, Tinlarebant, for treating Stargardt disease and geographic atrophy (GA). The company is conducting two studies for Stargardt disease: the Phase 3 DRAGON trial with 104 subjects and the Phase 2/3 DRAGON 2 trial targeting approximately 60 subjects. The Data Safety Monitoring Board (DSMB) recommended the DRAGON trial proceed without modifications and suggested regulatory review for drug approval, indicating promising interim results. For GA, the global Phase 3 PHOENIX trial has enrolled over 400 subjects and plans to increase to 500, reflecting strong enrollment progress. Financial metrics highlighted included R&D expenses of $29.9 million and a net loss of $36.1 million in 2024. The company ended the year with $31.7 million in cash and $113.5 million in investments, and they raised $15 million in February 2025, ensuring a full-year cash runway.Tinlarebant's Significant Advancements
Tinlarebant has been granted Rare Pediatric Disease and Fast Track designations in the U.S., Pioneer Drug designation in Japan, and Orphan Drug designation in the U.S., Europe, and Japan. The Phase 3 DRAGON trial interim analysis recommended proceeding without modifications, indicating promising efficacy.
Clinical Trial Enrollment Success
The DRAGON 2 trial has enrolled 11 of the targeted 60 subjects, and the PHOENIX trial for GA has over 400 subjects enrolled, with plans to increase to 500 due to good progress.
Financial Stability
Belite Bio ended 2024 with $31.7 million in cash and $113.5 million in investments, and raised $15 million in a direct offering, maintaining a full year's cash runway.
---
BLTE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BLTE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 17, 2025 | $67.44 | $67.81 | +0.55% |
| Nov 12, 2024 | $78.64 | $81.15 | +3.19% |
| Aug 09, 2024 | $49.48 | $48.55 | -1.88% |
| May 14, 2024 | $41.68 | $42.00 | +0.77% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Belite Bio, Inc. ADR (BLTE) report earnings?
Belite Bio, Inc. ADR (BLTE) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Belite Bio, Inc. ADR (BLTE) earnings time?
Belite Bio, Inc. ADR (BLTE) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BLTE EPS forecast?
BLTE EPS forecast for the fiscal quarter 2025 (Q1) is -0.35.
---